ArticleHormone research in paediatrics2026
Double Trouble: When Focal and Diffuse Hyperinsulinism Occur Simultaneously.
Article in Hormone research in paediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01916148 (Expanded Access Use of 18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Expanded Access Use of 18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
introductionCongenital hyperinsulinism (HI) may be diazoxide-responsive or diazoxide-unresponsive. Patients with diazoxide-unresponsive HI are further classified based on having the diffuse or focal form of the disease, with different management strategies associated with each form. While patients with HI typically have only one form of the disease, here we report 3 patients who had both focal and diffuse HI. CASE PRESENTATION: Three patients with diazoxide-unresponsive HI were transferred to our hospital for further management. All 3 patients had genetic testing which was equivocal or initially negative. Given their diazoxide status and not wanting to miss a focal lesion that was amenable to a surgical cure, all 3 patients underwent imaging with 18 F-L 3,4-dihydroxyphenylalanine positron emission tomography which identified focal pancreatic lesions in all 3 patients. They all had surgical resection of the lesions. Biopsies of the pancreas outside of the lesions noted rare or scattered islet cell nucleomegaly, indicative of diffuse disease, and subsequent fasting studies to determine if patients were cured revealed ongoing HI. Further review of genetic results suggested a mechanism for both focal and diffuse HI occurring in each of the patients. For all 3 patients, their ongoing HI could be managed with diazoxide following removal of the focal lesion.
conclusionFocal and diffuse HI can occur in the same patient. Following resection of focal pancreatic lesions, the patients require careful evaluations for evidence of ongoing HI, and depending on the genetic results, diazoxide may be a management option for ongoing HI in a subset of these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.